The invention providesopioid receptor agonists that are analgesic agents and that promote diminished side effects relative to a comparably effective dose of morphine. The side effects that are absent or attenuated include one or more of the following: constipation, respiratory depression, tolerance, dependence, nausea, confusion, sedation, hypotension, and post-treatment withdrawal symptoms.

The invention providesopioid receptor agonists that are analgesic agents and that promote diminished side effects relative to a comparably effective dose of morphine. The side effects that are absent or attenuated include one or more of the following: constipation, respiratory depression, tolerance, dependence, nausea, confusion, sedation, hypotension, and post-treatment withdrawal symptoms.

Provided is a composition for oral administration which includes a lipophilic active substance and a phospholipid, providing a prolonged therapeutic effect.

Provided is a composition for oral administration which includes a lipophilic active substance and a phospholipid, providing a prolonged therapeutic effect.

The present invention relates to a method for treating ocular inflammatory diseases in a subject in need of such treatment, which comprises administering a pharmaceutical composition comprising a therapeutically effective amount of at least one agonist of Formyl peptide receptor 2.

The present invention relates to compounds and methods which may be useful as treatments of neuromuscular diseases such as muscular dystrophy, and as inhibitors of NF-?B for the treatment or prevention of muscular wasting disease, including muscular dystrophy.

A peptide with anti-inflammatory activity is described, wherein the peptide comprises at least one amino acid sequence among SEQ ID NO: 2 to SEQ ID NO: 179, the peptide has above 80% homology of amino acid sequence with above-mentioned sequences, or the peptide is the fragment of the above-mentioned peptides. The peptides that have at least one amino acid sequence of SEQ ID NO: 2 to SEQ ID NO: 179 shows outstanding efficacy in both suppressing inflammation and in prophylactic means. Therefore, the composition comprising those peptides can be used as anti-inflammatory pharmaceutical compositions or as cosmetic compositions, in turn, treating and preventing a variety of different types of inflammatory diseases.

The present invention relates to, inter alia, combinations, methods, compositions, and oral dosage forms of a FAK inhibitor and a MEK inhibitor, for treating abnormal cell growth (e.g., cancer).

A method of antagonizing P2X.sub.3 and/or P2X.sub.2/3 receptors or treating a disease misregulation of P2X.sub.3 and/or P2X.sub.2/3 receptors treating a patient with a compound of formula I ##STR00001##
wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5 and R.sup.6 are as defined herein, or a pharmaceutically acceptable salt thereof. wherein, R.sup.1 is optionally substituted tetrazolyl, R.sup.2 is optionally substituted phenyl, optionally substituted pyridinyl or optionally substituted thienyl, and R.sup.3, R.sup.4, R.sup.5 and R.sup.6 are as defined herein. Also provided are methods of using the compounds for treating diseases associated with the P2X.sub.3 and/or a P2X.sub.2/3 receptor antagonist and methods of making the compounds.

The application is directed to compounds of Formula (I) and pharmaceutically acceptable salts and solvates thereof, wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, Y, and Z are defined as set forth in the specification. The invention is also directed to use of compounds of any one of Formulae I-VIII, and the pharmaceutically acceptable salts and solvates thereof, to treat disorders responsive to the modulation of one or more opioid receptors, or as synthetic intermediates. Certain compounds of the invention are especially useful for treating pain. ##STR00001##